LCTX
Lineage Cell Therapeutics Inc
Halal Rating :
Last Price
$0.59
Last updated:
Market Cap
-
7D Change
-2.14%
1 Year Change
-43.11%
Company Overview
Industries
Exchange
Next Earnings Date
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel cell therapies derived from human embryonic stem cells. The company's primary focus is on developing therapies for degenerative retinal diseases, neurological conditions, and cancer.
The company's lead product candidates include OpRegen® for the treatment of dry age-related macular degeneration, OPC1 for spinal cord injuries, and VAC2 for cancer immunotherapy.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $3.78m | $7.62m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $1.41m | $7.28m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $1.44m | $8.11m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Lineage Cell Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.